<SEC-DOCUMENT>0001157523-21-001089.txt : 20210825
<SEC-HEADER>0001157523-21-001089.hdr.sgml : 20210825
<ACCEPTANCE-DATETIME>20210825090024
ACCESSION NUMBER:		0001157523-21-001089
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210825
FILED AS OF DATE:		20210825
DATE AS OF CHANGE:		20210825

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FSD Pharma Inc.
		CENTRAL INDEX KEY:			0001771885
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39152
		FILM NUMBER:		211204094

	BUSINESS ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 3400
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
		BUSINESS PHONE:		(416) 854-8884

	MAIL ADDRESS:	
		STREET 1:		FIRST CANADIAN PLACE
		STREET 2:		100 KING STREET WEST, SUITE 3400
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1A4
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a52478064.htm
<DESCRIPTION>FSD PHARMA INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.5.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
  <div>
    <div>
      <div style="font-family: 'Times New Roman',Times,serif;"><br>
      </div>
      <div style="text-align: center; margin-right: 14.2pt; margin-left: 16.3pt; margin-top: 4.55pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; margin-right: 14.1pt; margin-left: 16.3pt; margin-top: 0.5pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="text-align: center; margin-right: 13.8pt; margin-left: 16.3pt; margin-top: 0.5pt; color: #231F20; font-weight: bold;">Washington, D.C. 20549</div>
      <div style="margin-top: 0.5pt; font-family: 'Times New Roman',Times,serif;"><br>
      </div>
      <div style="text-align: center; margin-right: 13.3pt; margin-left: 16.3pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">Form 6-K</div>
      <div style="text-align: center; margin-right: 13.75pt; margin-left: 16.3pt; margin-top: 12.9pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; font-weight: bold;">
        <div style="margin-bottom: 8pt;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE<br>
          SECURITIES EXCHANGE ACT OF 1934</div>
      </div>
      <div style="margin-top: 0.35pt; font-family: 'Times New Roman',Times,serif;"><br>
      </div>
      <div><font style="font-family: 'Times New Roman',Times,serif; color: rgb(35, 31, 32);">For the month of </font><u><font style="font-family: 'Times New Roman',Times,serif; color: rgb(35, 31, 32);">August</font><font style="font-family: 'Times New Roman',Times,serif; color: rgb(35, 31, 32);">, 20</font></u><font style="font-family: 'Times New Roman',Times,serif; color: rgb(35, 31, 32);"><u>21</u>.</font><font style="display: inline-block; width: 265.95pt; font-family: 'Times New Roman',Times,serif;" id="TRGRRTFtoHTMLTab"></font></div>
      <div style="text-align: center;"><font style="display: inline-block; width: 265.95pt; font-family: 'Times New Roman',Times,serif;" id="TRGRRTFtoHTMLTab"> </font><font style="font-family: 'Times New Roman',Times,serif; color: rgb(35, 31, 32);"></font></div>
      <div style="text-align: center;"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(35, 31, 32);"> <br>
        </font></div>
      <div><font style="font-family: 'Times New Roman',Times,serif; color: rgb(35, 31, 32);">Commission File Number <u>001-39152</u></font></div>
      <div><font style="font-family: 'Times New Roman',Times,serif; color: rgb(35, 31, 32);"><u> <br>
          </u></font></div>
      <div style="text-align: center; margin-top: 0.45pt; font-family: 'Times New Roman',Times,serif; font-size: 16pt;">
        <table cellspacing="0" cellpadding="0" border="0" id="z41843b754346438e82d5e5c5dddadfd9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 100%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;"><font style="font-size: 16pt;">FSD PHARMA INC.</font> <br>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;">(Translation of registrant&#8217;s name into English) <br>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;">&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 100%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center;">199 Bay Street, Suite 4000, Toronto, ON M5L 1A9, Canada <br>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 100.00%;">
                <div style="text-align: center;">(Address of principal executive office) <br>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <br>
      <div style="margin-top: 0.05pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;"><font style="font-size: 10pt; color: rgb(35, 31, 32);">Indicate by check mark whether the registrant files or will file annual reports under cover of Form
          20-F or Form 40-F.</font></div>
      <div style="margin-top: 0.05pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt;"><font style="font-size: 10pt; color: rgb(35, 31, 32);">Form 20-F </font><font style="font-size: 10pt;">&#9744;</font><font style="font-size: 10pt; color: rgb(35, 31, 32);">&#160;</font><font style="font-size: 10pt; color: rgb(35, 31, 32);">Form 40-F </font><font style="font-size: 10pt;">&#9746;</font></div>
      <div style="margin-top: 9.85pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; text-indent: 8pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</div>
      <div style="margin-top: 0.3pt; font-family: 'Times New Roman',Times,serif;"><br>
      </div>
      <div style="margin-top: 0.05pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Note</font>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to
        provide an attached annual report to security holders.</div>
      <div style="margin-top: 9.65pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____<font style="display: inline-block; width: 12pt;" id="TRGRRTFtoHTMLTab"> <br>
        </font></div>
      <div style="margin-top: 0.45pt; font-family: 'Times New Roman',Times,serif;"><br>
      </div>
      <div style="margin-top: 4.6pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif;"><font style="font-weight: bold;">Note</font>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish
        a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or
        under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders,
        and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.</div>
      <div style="font-family: 'Times New Roman',Times,serif;">
        <div><br>
        </div>
      </div>
      <div style="font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: justify; color: rgb(0, 0, 0);">Exhibit 99.1 to this Form 6-K is hereby filed and incorporated by reference into the registrant&#8217;s Registration Statement on Form F-10 (Commission File No. 333-236780).</div>
        <div style="text-align: justify; color: rgb(0, 0, 0);"> <br>
        </div>
      </div>
      <div style="font-family: 'Times New Roman',Times,serif;">
        <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">EXPLANATORY NOTE</div>
      </div>
      <div>
        <div style="margin-top: 12pt; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">This&#160;Form&#160;6-K&#160;is being filed solely to incorporate by reference Exhibit 99.1 to this&#160;Form&#160;6-K&#160;into the registrant&#8217;s Registration Statement on
          Form&#160;F-10&#160;(Commission File No. 333-236780).</div>
        <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div id="DSPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
      </div>
      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
      <div style="margin-top: 0.45pt; font-family: 'Times New Roman',Times,serif;"><br>
      </div>
      <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; text-indent: 8pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
        undersigned, thereunto duly authorized.</div>
      <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif; text-indent: 8pt;"> <br>
      </div>
      <div style="font-family: 'Times New Roman',Times,serif;">
        <table cellspacing="0" cellpadding="0" border="0" id="z87ae6c4d0b514084a2449816cc8d23b5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 5%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 40%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td colspan="2" rowspan="1" style="width: 5%; text-indent: 48pt; border-bottom: 2px solid rgb(0, 0, 0);"><font style="font-family: 'Times New Roman',Times,serif;">FSD Pharma Inc.</font></td>
            </tr>
            <tr>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 40%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td colspan="2" rowspan="1" style="width: 5%; text-indent: 104pt;">(Registrant)</td>
            </tr>
            <tr>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 40%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 45%;">
                <div>&#160;</div>
              </td>
            </tr>
            <tr>
              <td style="width: 5%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>Date <br>
                </div>
              </td>
              <td style="width: 40%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>August 25, 2021 <br>
                </div>
              </td>
              <td style="width: 5%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%; padding-bottom: 2px;">
                <div style="text-align: center;">By <br>
                </div>
              </td>
              <td style="width: 45%; padding-bottom: 2px;">
                <div style="text-indent: 32pt;">/s/ Nathan Coyle <br>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 5%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 40%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%; padding-bottom: 2px;">
                <div>&#160;</div>
              </td>
              <td style="width: 45%; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-indent: 40pt;">(Signature) * <br>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 40%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%;">
                <div>&#160;</div>
              </td>
              <td style="width: 45%;">
                <div style="text-indent: 8pt;">Nathan Coyle, Chief Financial Officer <br>
                </div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <br>
    <hr noshade="noshade" align="left" style="height: 1px; width: 10%; color: #000000; background-color: #000000; margin-left: 0px; margin-right: auto; border: none;">
    <div style="margin-top: 0.6pt; color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif;">* Print the name and title under the signature of the signing officer.<font style="display: inline-block; width: 12pt;" id="TRGRRTFtoHTMLTab">&#160;</font></div>
    <div style="margin-top: 0.45pt; font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="color: rgb(35, 31, 32); font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div>
      <div style="font-family: 'Times New Roman',Times,serif;">
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="font-family: 'Times New Roman',Times,serif;"><br>
      </div>
      <div style="font-family: 'Times New Roman',Times,serif;">
        <table cellspacing="0" cellpadding="0" border="0" id="z531677d054d0450a86fd3c5b362d1dec" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 20%; text-align: left; vertical-align: middle;">
                <div>SEC 1815 (09-18) <br>
                </div>
              </td>
              <td style="width: 80%; text-align: left; vertical-align: middle;">
                <div>
                  <div>
                    <div style="color: rgb(35, 31, 32); font-weight: bold;">Persons who are to respond to the collection of information contained&#160; in this form are not required to respond unless the form displays a currently valid OMB control number. <br>
                    </div>
                  </div>
                </div>
              </td>
            </tr>

        </table>
      </div>
      <div style="margin-top: 0.35pt; font-family: 'Times New Roman',Times,serif;"><br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <br>
    </div>
    <div style="text-align: center; margin-top: 0.05pt; font-family: 'Times New Roman',Times,serif;">EXHIBIT INDEX</div>
    <div style="margin-top: 0.05pt; font-family: 'Times New Roman',Times,serif;"><br>
    </div>
    <div style="margin-top: 0.05pt;"><br>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 15%;">
              <div><font style="font-family: 'Times New Roman',Times,serif;"><u>Exhibit</u></font></div>
            </td>
            <td style="width: 85%; font-weight: normal;">
              <div>
                <div>
                  <div style="color: rgb(35, 31, 32);"><font style="font-family: 'Times New Roman',Times,serif;"><u>Description</u></font></div>
                </div>
              </div>
            </td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 15%;">&#160;</td>
            <td rowspan="1" style="width: 85%;">&#160;</td>
          </tr>
          <tr>
            <td rowspan="1" style="width: 15%;"><font style="font-family: 'Times New Roman',Times,serif;">*<a href="a52478064_ex991.htm">Exhibit 99.1</a></font> <br>
            </td>
            <td rowspan="1" style="width: 85%;"><a href="a52478064_ex991.htm"><font style="font-family: 'Times New Roman',Times,serif;">News Release dated August
                  25, 2021</font></a> <br>
            </td>
          </tr>

      </table>
    </div>
    <div style="margin-top: 0.05pt;"><font style="display: inline-block; width: 144pt; font-family: 'Times New Roman',Times,serif;" id="TRGRRTFtoHTMLTab">&#160;</font><font style="font-family: 'Times New Roman',Times,serif;"><u></u></font></div>
    <div style="margin-top: 0.05pt; font-family: 'Times New Roman',Times,serif;">
      <hr noshade="noshade" align="left" style="height: 1px; width: 10%; color: #000000; background-color: #000000; margin-left: 0px; margin-right: auto; border: none;"></div>
    <div style="margin-top: 0.05pt;"><font style="display: inline-block; width: 180pt; font-family: 'Times New Roman',Times,serif;" id="TRGRRTFtoHTMLTab"></font><br>
    </div>
    <div style="font-family: 'Times New Roman',Times,serif;">
      <div style="color: rgb(0, 0, 0);">*Previously filed</div>
    </div>
    <div style="margin-top: 0.05pt; font-family: 'Times New Roman',Times,serif;"><br>
    </div>
  </div>
  <font style="font-family: 'Times New Roman',Times,serif;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a52478064_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.5.0.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div>
    <div class="bw-release">
      <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>FSD Pharma Announces Definitive Agreement to Acquire Lucid Psycheceuticals</b> </h1>
      <div class="bw-release-subhead">
        <p style="text-align: center; list-style-position: inside;"><b> <i>Acquisition Advances Company&#8217;s Strategic Plan Toward a Diversified Novel Drug Development Pipeline in Psychedelics and Medical Cannabis </i> </b></p>
      </div>
      <div class="bw-release-body">
        <div class="bw-release-table-js bw-release-story">
          <p>TORONTO--(BUSINESS WIRE)--August 25, 2021--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (&#8220;<b>FSD Pharma</b>&#8221; or the &#8220;<b>Company</b>&#8221;), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions
            in legal psychedelics and medical cannabis, announced today it has entered a definitive agreement to acquire 100% of the issued and outstanding shares Lucid Psycheceuticals Inc. (&#8220;<b>Lucid</b>&#8221;), a Canadian-based specialty psychedelic
            pharmaceutical company focused on the development of therapies to treat critical neurodegenerative diseases, for approximately US$9 million (CAD$11.3 million) in FSD Pharma stock (the &#8220;<strong>Transaction</strong>&#8221;), as further described below.
          </p>
          <p> &#8220;The acquisition of a distinctive company like Lucid illustrates FSD Pharma&#8217;s vision to build a portfolio of biotechnology assets on a new frontier of medicine that hold the potential to treat mental health disorders and neurodegenerative
            diseases in a new way,&#8221; said Anthony Durkacz, Interim CEO of FSD Pharma. &#8220;Lucid has successfully developed a strong pipeline of novel therapeutic compounds &#8212; supported by IP in order to advance to future clinical trials &#8212; and we are confident
            that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies. This is an exciting venture for FSD Pharma that we believe represents a
            paradigm shift in the development and outlook of our company.&#8221; </p>
          <p> <b>Strategic Highlights</b> </p>
          <p> Founded in 2020, Lucid is developing novel molecules and combinations with the goal of addressing Total Brain Health and targeting some of the most challenging neurodegenerative diseases, such as Multiple sclerosis, and other Brain
            conditions. Lucid has exclusive worldwide licensing rights from the University Health Network, North America&#8217;s largest health research organization, to a patent-protected family of new chemical entities (NCEs), on which Lucid&#8217;s development
            platform is based and from which its lead neurodegenerative disorders therapeutic candidate, Lucid-21-302, has been derived. In addition, Lucid&#8217;s pipeline includes Lucid-201, a psychedelic drug candidate targeting mental health disorders, and
            it is also investigating certain cannabinoids. </p>
          <p> In addition, upon closing of the transaction Lucid&#8217;s co-founder and CEO, Dr. Lakshmi Kotra will be transitioning to the FSD Pharma team with Prof. Kotra taking on the role of leading the development of FSD Pharma&#8217;s drug development pipeline
            in Psychedelics and Medical Cannabis. Dr. Kotra is a Professor of Medicinal Chemistry at the University of Toronto, and senior scientist at Krembil Brain Institute at the University Health Network. </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> Prof. Lakshmi Kotra, co-founder and CEO of Lucid, commented, &#8220;We started with a vision to accelerate therapies for Total Brain Health. Since inception, we have made significant progress and built a strong scientific and execution team. We are
            excited to enter a new phase of growth with FSD Pharma. I am personally delighted with FSD Pharma leadership&#8217;s shared commitment to bring forward advanced therapeutics addressing challenging health issues. We believe our combined resources and
            experienced teams will position us to enter clinical development programs to deliver highly effective therapeutic products in neurodegenerative disorders and mental health areas.&#8221; </p>
          <p> <b>Transaction Details</b> </p>
          <p> The Transaction will be effected by way of a three-cornered amalgamation between Lucid, FSD Pharma and a wholly-owned subsidiary of FSD Pharma. The Transaction will involve the issuance of approximately 4.5 million Class B subordinate voting
            shares in the capital of FSD Pharma (each, an &#8220;<b>FSD Share</b>&#8221;) as the acquisition consideration (the &#8220;<strong>Consideration Shares</strong>&#8221;), with a deemed aggregate purchase price of approximately US$9 million (CAD$11.3 million based on an
            exchange rate of US$1 to CAD$1.255) at a deemed price of US$2.00 (CAD$2.51) per FSD Share. The <strong>Consideration Shares</strong> may be adjusted slightly in the event the market price of the FSD Shares changes significantly prior to
            closing of the Transaction. Additionally, all of the outstanding Lucid stock options and warrants will become exercisable into FSD Shares, with the number and exercise price of such securities to be adjusted in accordance with the Transaction&#8217;s
            exchange ratio. </p>
          <p> The closing of the Transaction is subject to customary closing conditions for a transaction of this nature including, among other things, Lucid obtaining the requisite shareholder approval at a special meeting of Lucid shareholders to be
            called to consider the Transaction (the &#8220;<b>Lucid Meeting</b>&#8221;). The closing of the Transaction is expected to occur in September 2021. </p>
          <p> The Transaction will require approval by 66 2/3% of the votes cast by Lucid shareholders at the Lucid Meeting. Lucid shareholders holding at least 66 2/3% of the shares of Lucid, have entered into support agreements with FSD Pharma (the &#8220;<b>Support
              Agreements</b>&#8221;) pursuant to which, among other things, they have agreed to vote all of the shares held by them in favor of the Transaction at the Lucid Meeting, on the terms and subject to the conditions set forth in the Support Agreements.
          </p>
          <p> Additionally, it is a condition to closing of the Transaction that Lucid shareholders holding approximately 44% of the shares of Lucid, shall have entered into lock-up agreements with FSD Pharma pursuant to which: (a) 20% of the Consideration
            Shares received by each such locked-up shareholder will be exempt from any contractual transfer restrictions imposed by FSD Pharma; and (b) 80% of the Consideration Shares received by each such locked-up shareholder will be subject to
            contractual transfer restrictions, with such Consideration Shares to be released from such transfer restrictions over an 18 month period from the date of closing the Transaction. </p>
          <div> </div>
          <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
            <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
              <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
          </div>
          <p> Completion of the Transaction is subject to various closing conditions, including: the approval of the Nasdaq and CSE, the approval of the boards of directors of FSD Pharma and Lucid, the approval of the security holders of Lucid, and
            completion of due diligence by the parties. </p>
          <p> Anthony Durkacz, a director and control person of the Company, is also a shareholder and warrant holder of Lucid, through a company he beneficially owns, and consequently the Transaction constitutes a "related party transaction" within the
            meaning of Multilateral Instrument 61-101 - <i>Protection of Minority Security Holders in Special Transactions</i> ("<b>MI 61-101</b>"). In its consideration and approval of the Transaction, the board of directors of the Company, with Mr.
            Durkacz recusing himself, determined that the Transaction will be exempt from the formal valuation and minority approval requirements of MI 61-101 on the basis of the exemptions in Sections 5.5(a) and 5.7(1)(a) of MI 61-101. </p>
          <p> <b>About FSD Pharma</b> </p>
          <p> FSD Pharma is a life sciences holding company dedicated to building a portfolio of diversified therapeutic assets and innovative healthcare and biotech services. Currently, FSD is actively pursuing potential acquisition targets in the
            healthcare and biotech space to bring innovative treatments to market to treat various mental health disorders and neurodegenerative diseases. www.fsdpharma.com </p>
          <p> <b>About Lucid Psycheceuticals</b> </p>
          <p> The brain is the ultimate frontier in health research. Depression, anxiety, dementia and similar conditions often are prodromes to more serious neurodegenerative diseases, such as Multiple sclerosis, Alzheimer's disease and Parkinson's
            disease. Inspired by the mechanisms of action of psychedelics, and the need for therapeutics to prevent, and possibly reverse, neurodegeneration, Lucid is exploring novel therapies to address total brain health, i.e. mind and biology behind it!
            For more information, please visit www.lucidpsycheceuticals.com. </p>
          <p> <b>Forward Looking Information</b> </p>
          <p> Certain statement contained herein are &#8220;forward-looking statements&#8221;. Often, but not always, forward-looking statement can be identified by the use of words such as &#8220;plans&#8221;, &#8220;expects&#8221;, &#8220;expected&#8221;, &#8220;scheduled&#8221;, &#8220;estimates&#8221;, &#8220;intends&#8221;,
            &#8220;anticipates&#8221; or &#8220;believes&#8221;, or variations of such words and phrases, or states that certain actions, events or results &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;might&#8221; or &#8220;will&#8221; be taken, occur or be achieved. Forward-looking statements contained in this
            press release include the comments made with respect to the Company&#8217;s clinical trial, the evaluation of the commercial viability of its principal drug compound, and the statements made by Zeeshan Saeed regarding the commercial opportunities the
            Company&#8217;s principal drug compound and other commercial opportunities and fulfilling strategic and operational goals outlined in prior communications to shareholders. FSD cannot give any assurance that such forward-looking statements will prove
            to have been correct. The reader is cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. </p>
        </div>
        <div class="bw-release-contact">
          <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
          <p> Zeeshan Saeed, President, Founder and Director, FSD Pharma Inc. <br>
            Email: zeeshan@fsdpharma.com, Telephone: (416) 854-8884 <br>
            Investor Relations: Email: ir@fsdpharma.com, Website: www.fsdpharma.com<br>
            KCSA Strategic Communications <br>
            Fsdpharma@kcsa.com </p>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
